...
首页> 外文期刊>Case Reports in Gastrointestinal Medicine >Metastatic Hepatocellular Carcinoma in a Patient with Crohn’s Disease Treated with Azathioprine and Infliximab: A Case Report and Literature Review
【24h】

Metastatic Hepatocellular Carcinoma in a Patient with Crohn’s Disease Treated with Azathioprine and Infliximab: A Case Report and Literature Review

机译:硫唑嘌呤和英夫利昔单抗治疗克罗恩病患者的转移性肝细胞癌:一例病例报告并文献复习

获取原文
           

摘要

Hepatocellular carcinoma most commonly occurs in patients with underlying liver disease or cirrhosis. We describe a case of hepatocellular carcinoma in a 34-year-old man with Crohn’s disease treated with azathioprine and infliximab. The patient had no history of liver disease and a complete autoimmune and viral workup was unremarkable. Unfortunately, the patient developed widespread metastatic disease and passed away 5 months after his initial diagnosis. The mechanism of hepatocellular carcinoma in patients’ with Crohn’s disease is poorly understood and may include both autoimmunity and treatment-related complications. Previous case reports suggest the possibility of a concerning association between azathioprine therapy and the development of hepatocellular carcinoma in patients with Crohn’s disease. Clinicians may consider early imaging in patients with Crohn’s disease presenting with concerning symptomatology or abnormal liver enzymes, especially in those being treated with azathioprine alone or in combination with infliximab. Future research may help to uncover additional risk factors for this exceedingly rare diagnosis in this patient population.
机译:肝细胞癌最常见于潜在肝病或肝硬化患者。我们描述了一个用硫唑嘌呤和英夫利昔单抗治疗的34岁克罗恩病患者的肝细胞癌病例。该患者无肝病史,完全自身免疫和病毒检查无异常。不幸的是,患者发展出广泛的转移性疾病,并在其最初诊断后5个月去世。对克罗恩病患者肝细胞癌的机制了解甚少,可能包括自身免疫和治疗相关并发症。先前的病例报告表明,在克罗恩病患者中,硫唑嘌呤治疗与肝细胞癌的发展之间存在相关联的可能性。临床医生可能会考虑对出现症状或肝酶异常的克罗恩病患者进行早期影像学检查,尤其是那些单独接受硫唑嘌呤或联合英夫利昔单抗治疗的患者。未来的研究可能有助于发现该患者人群中这种极为罕见的诊断的其他危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号